Corrections to "A Machine-Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design" [0.03%]
《基于机器学习的亨廷顿病进展模型：对临床试验设计的启示》的更正
Amrita Mohan,Zhaonan Sun,Soumya Ghosh et al.
Amrita Mohan et al.
Reply to: "GNAO1 Haploinsufficiency Associated with a Mild Delayed-Onset Dystonia Phenotype" [0.03%]
《回复：“与轻微迟发性 dystonia 表型相关的 GNAO1 半合子不足”》
注：由于"dystonia"是一种医学术语，指的是肌张力障碍或肌痉挛，通常在翻译时保留其英文形式以确保准确性。如果需要将 "dystonia" 翻译成中文，则可以使用“肌张力障碍”。因此，另一个可能的翻译是：
《回复：“与轻微迟发性肌张力障碍表型相关的 GNAO1 半合子不足”》
Thomas Wirth,Giacomo Garone,Manju A Kurian et al.
Thomas Wirth et al.
Effect of Amyloid on Cognitive Performance in Parkinson's Disease and Dementia with Lewy Bodies [0.03%]
淀粉样蛋白对帕金森病和路易体痴呆的认知功能的影响
Kyoungwon Baik,Hye Ryun Kim,Mincheol Park et al.
Kyoungwon Baik et al.
Background: Concomitant amyloid pathology contributes to the clinical heterogeneity of Lewy body diseases (LBDs). Objective: The object...
Clues to Reshaping Anti-α-Synuclein Immunotherapy in Early Parkinson's Disease Patients [0.03%]
早期帕金森病患者重塑抗-α-突触核蛋白免疫治疗的线索
Giovanni Palermo,Roberto Ceravolo
Giovanni Palermo
Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson's Disease and Related Disorders [0.03%]
Parkinson病及相关疾病中反映突触功能障碍的脑脊液生物标记物发生改变
Johanna Nilsson,Julius Constantinescu,Bengt Nellgård et al.
Johanna Nilsson et al.
Background: Synaptic dysfunction and degeneration are central contributors to the pathogenesis and progression of parkinsonian disorders. Therefore, identification and validation of biomarkers reflecting pathological syna...
It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum [0.03%]
既如此则一直如此：MDS-UPDRS第三部分的评分不能与其他部分结合起来给出一个有效的总分
Christopher G Goetz,Dongrak Choi,Yuanyuan Guo et al.
Christopher G Goetz et al.
Background: Original clinimetric analyses by the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) developers did not confirm the validity of summing the scores of it...
Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD [0.03%]
LRRK2-PD中路易体病理的脑和脑脊液α-突触核蛋白实时震诱导转化法检测
Alicia Garrido,Graham Fairfoul,Eduardo Tolosa et al.
Alicia Garrido et al.
Background: The neuropathology of Parkinson's disease (PD) associated with leucine-rich repeat kinase 2 (LRRK2) mutations (LRRK2-PD) is heterogeneous and varies with the type of mutation. There are only a few studies eval...
Results of a Randomized Clinical Trial of Speech After Early Neurostimulation in Parkinson's Disease [0.03%]
早期神经刺激对帕金森病患者言语能力影响的随机临床试验结果
Serge Pinto,Adelheid Nebel,Jörn Rau et al.
Serge Pinto et al.
Background: The EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN-DBS) and best medical treatment (BMT) was superior t...
Randomized Controlled Trial
Movement disorders : official journal of the Movement Disorder Society. 2023 Feb;38(2):212-222. DOI:10.1002/mds.29282 2023
Somatic SNCA Copy Number Variants in Multiple System Atrophy are Related to Pathology and Inclusions [0.03%]
多系统萎缩症中体细胞SNCA拷贝数变异与病理和包涵体相关
Monica Emili Garcia-Segura,Diego Perez-Rodriguez,Darren Chambers et al.
Monica Emili Garcia-Segura et al.
Background: Somatic α-synuclein (SNCA) copy number variants (CNVs, specifically gains) occur in multiple system atrophy (MSA) and Parkinson's disease brains. ...
Practically Defined Off-State Dyskinesia Following Repeated Intraputamenal Glial Cell Line-Derived Neurotrophic Factor Administration [0.03%]
重复纹状体内施用神经生长因子后实际定义的关期异动症
Katherine Lloyd,Michael Lawton,Alan Whone
Katherine Lloyd
Background: We recently showed that by employing an enhanced drug-delivery approach, repeated administration of glial cell line-derived neurotrophic factor (GDNF) can produce a spatially distributed increased 18 F-DOPA po...